[Is there any desensitization of presynaptic alpha 2-adrenergic receptors in hypertension? Experimental and clinical studies]. 1992

C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
Laboratoire de pharmacologie médicale et clinique, INSERM U 317, Centre hospitalier universitaire Purpan, faculté de médecine, Toulouse.

Several authors have discussed an alteration of adrenergic receptivity in arterial hypertension. De Champlain (Hypertension 1990; 8: S77-S85) suggested that postsynaptic alpha 1-adrenergic functions became dominant while beta-adrenergic functions are attenuated in arterial hypertension. However, the status of presynaptic alpha 2-adrenoceptors remains unknown. The present study investigates presynaptic alpha 2-adrenoceptors in hypertension through the measurement of plasma levels of noradrenaline after administration of yohimbine, an alpha 2-adrenoceptor antagonist, in essential hypertension. Yohimbine (0.2 mg/kg per os) induced a 73% increase of plasma levels of noradrenaline in hypertensive patients (n = 12) and a 178% one in normotensive subjects (n = 6, p < 0.05). A similar significant difference was found in experimental neurogenic hypertension observed in awake dogs 3 weeks after sinoaortic denervation: the increase in plasma concentrations of noradrenaline after yohimbine (0.5 mg/kg i.v.) was +279% in hypertensive versus +642% in normotensive dogs (p < 0.05). The results show that the magnitude of the yohimbine-induced sympathetic activation is lower in hypertensives than in normotensives. They suggest the existence of a presynaptic alpha 2-adrenoceptor desensitization in arterial hypertension. The abnormality of this presynaptic inhibitory mechanism can increase the sympathetic tone and help to develop and maintain arterial hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003714 Denervation The resection or removal of the nerve to an organ or part. Laser Neurectomy,Neurectomy,Peripheral Neurectomy,Radiofrequency Neurotomy,Denervations,Laser Neurectomies,Neurectomies,Neurectomies, Laser,Neurectomies, Peripheral,Neurectomy, Laser,Neurectomy, Peripheral,Neurotomies, Radiofrequency,Neurotomy, Radiofrequency,Peripheral Neurectomies,Radiofrequency Neurotomies
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
June 1995, Pharmacology & toxicology,
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
January 1987, Hypertension (Dallas, Tex. : 1979),
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
January 1990, Psychosomatic medicine,
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
December 2001, Journal of hypertension,
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
July 1986, Archives internationales de pharmacodynamie et de therapie,
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
March 1988, Archives internationales de physiologie et de biochimie,
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
May 1981, The American journal of psychiatry,
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
June 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
March 1983, Clinical science (London, England : 1979),
C Damase-Michel, and G Tavernier, and M E Llau, and F Chollet, and J M Sénard, and H Bagheri, and M A Tran, and G Houin, and B Guiraud-Chaumeil, and J L Montastruc
February 1983, Biochemical and biophysical research communications,
Copied contents to your clipboard!